Oncology
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE
Dec 05, 2018
by [Charles E. Geyer, Jr., Chiun-Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andrés Redondo, Hans H. Fischer, William Jacot, Alison K. Conlin, Claudia Arce-Salinas, Irene L. Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John P. Crown, Pia Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie Smitt, Hannah Douthwaite, Stina M. Singel, and Gunter von Minckwitz, on behalf of the KATHERINE investigators ]
KATHERINE is a Phase III study of T-DM1 vs trastuzumab in patients with HER2+ early breast cancer who had residual disease after receiving neoadjuvant trastuzumab containing therapy (some patients also received pertuzumab). These are the primary data from the study which is the first study to include such a high-risk group of patients.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Preparing document for printing…
0%
Receive this presentation and more content via email
Related Content
-
Also In SABCS 2018:
Delayed initiation of adjuvant chemotherapy significantly impacts survival in women with triple-negative breast cancer
-
Also In SABCS 2018:
SABCS poster 2018: Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized Phase III study in Asian patients (PEONY)
-
Also In SABCS 2018:
Daily report from SABCS 2018: Wednesday 5th December by Springer Healthcare